Brief: Castle Biosciences said Decisiondx-SCC Test Was Able To Stratify 3-Year Metastasis Free Survival Rates
12/06/2023 12:02
June 12 (Reuters) - Castle Biosciences Inc CSTL.O :
* CASTLE BIOSCIENCES - DECISIONDX-SCC TEST WAS ABLE TO
STRATIFY
3-YEAR METASTASIS FREE SURVIVAL RATES WITHIN AJCC8 AND BWH T1
POPULATIONS OF CSCC COHORT
Source text for Eikon: ID:nBw1z5j3ca
Further company coverage: CSTL.O
Recent news on Castle Biosciences
See all newsBrief: Castle Biosciences, - Opens New Laboratory And Office Facility In Scottsdale, Arizona
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million